

Non Hodgkin Lymphoma (NHL)

A study to look at how safe different doses of the study medicine - DCDS0780A - were for patients with non-Hodgkin's Lymphoma that involved B cells

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02453087 GO29687

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma. In the combination portion of the study, the safety and tolerability of DCDS0780A in combination with rituximab or obinutuzumab will be assessed.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02453087 GO29687
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No

DCDS0780A is a new medicine known as an antibody-drug conjugate or "ADC". Patients with non-Hodgkin's Lymphoma that involved B cells received different doses of DCDS0780A to help researchers find out which dose was safe. In a second part to this study, patients got DCDS0780A with an approved medicine called "rituximab". Researchers wanted to know if DCDS0780A was safe when used with rituximab.